A dermal matrix that puts you in control of wound healing.
AS EARLY AS
5-DAY
Graft readiness1,2*
11-day average graft readiness1*
97%
Autograft take
compared to 85% and 68% seen with leading competitors3†
4x
Less wound contraction
compared to leading competitors3†
0%
Infection rate
versus up to 70% with leading competitors3†
Cohealyx is bioengineered for full-thickness wound management to help physicians achieve definitive closure sooner by preparing wounds for grafting in as few as 5 days.1,2
Cohealyx redefines wound bed preparation by empowering providers to act early, graft sooner, and reduce complications.1 Whether managing burns, trauma wounds, surgical dehiscence, or fasciotomies, Cohealyx is designed for real-world efficiency.
50% faster graft readiness1*‡
- Median: 11 days
- Earliest: 5 days
- 25% graft-ready within 7 days
- 72% graft-ready within 14 days
- 90% investigator satisfaction
‡ A meta analysis including 873 patients treated with leading competitors found a mean time to grafting of 33 days.1,4
Built to support wound bed revascularization and aesthetic outcomes.
TetraPure™ Technology
Uniquely purified and bioengineered with ideal pore structure for integration into the wound bed and revascularization.2,3
Balanced collagen composition
Purified from young bovine dermis, Cohealyx contains Type I and Type III collagen. Type III collagen is linked to reduced scarring and contraction.5-8
Real-world outcomes: Patient case
Fast graft readiness by day 5 after a failed autograft in a high risk patient
After an autograft failure, this diabetic patient’s care team turned to Cohealyx for revascularization support.
Highlights:
- Fully incorporated into the wound bed within 5 days
- Autografting completed on day 7
- 100% graft take by postoperative day 3
67-year-old female
(un-hydrated)
NPWT=negative pressure wound therapy. Photos Courtesy of Dr. John Loftus (The Ohio State University, Wexner Medical Center).
The right size for the right wound.
Cohealyx collagen dermal matrix is available in several sizes to meet wound management demands.
| MODEL | DEsCRIPTION | SIZE (CM) | CM2 | UNITS/BOX |
|---|---|---|---|---|
| BDCDM24 | Cohealyx collagen dermal matrix | 2×4 | 8 | 1 |
| BDCDM55 | Cohealyx collagen dermal matrix | 5×5 | 25 | 1 |
| BDCDM1010 | Cohealyx collagen dermal matrix | 10×10 | 100 | 1 |
| BDCDM1020 | Cohealyx collagen dermal matrix | 10×20 | 200 | 1 |
| BDCDM2035 | Cohealyx collagen dermal matrix | 20×35 | 700 | 1 |
Resources that support you and your patients
AVITA Medical is available to assist you with your coding and reimbursement questions. See our coding guide for information about coding for the use of Cohealyx:
For general coding, coverage, and reimbursement questions that do not involve specific cases or patient health information, please e-mail us at: hema@avitamedical.com
For more in-depth support with benefits verification, prior authorization, appeals, or case-specific inquiries, please contact AVITA Patient Access Services at:
- E-mail: AVITA@alconj.org
- Phone: 1-866-965-3020
- Fax: 1-866-635-2270
*Based on clinical study data.
† Based on preclinical study data.
References
- ClinicalTrials.gov identier: NCT06787690. Interim Analysis. Publica-
tion in Progress. - Akpunonu C, et al. J Surg. 2025;10(07):11337.
- Bush KA, et al. Cureus. 2025;17(3):e81517.
- Crombie RE. Establishing Clinical Benchmarks for Dermal Matrices in Full-thickness Wound Management: Analysis of Role in Complex Closure. Presented at the ABA Annual Meeting; Orlando, FL; April 14-17, 2026
- Internal data on le: SDS-PAGE Analysis.
- Ramshaw JA. Connect Tissue Res. 1986;14(4):307-14.
- Ehrlich HP. Eye (Lond). 1988;2 (Pt 2):149-57.
- Zoppi N, et. al. J Biol Chem. 2004 Apr 30;279(18):18157-68.